Solid Biosciences's Total Assets for the quarter that ended in Dec. 2023 was $164.94 Mil.
During the past 12 months, Solid Biosciences's average Total Assets Growth Rate was -11.20% per year.
During the past 3 years, the average Total Assets Growth Rate was 36.00% per year.
During the past 5 years, the average Total Assets Growth Rate was 23.40% per year.
During the past 9 years, Solid Biosciences's highest 3-Year average Total Assets Growth Rate was 281.30%. The lowest was 12.80%. And the median was 34.30%.
The historical data trend for Solid Biosciences's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Solid Biosciences's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Solid Biosciences (NAS:SLDB) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Dec. 2023) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Solid Biosciences's Asset Turnover for the quarter that ended in Dec. 2023 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Solid Biosciences Total Assets Related Terms
Thank you for viewing the detailed overview of Solid Biosciences's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Solid Biosciences (Solid Biosciences) Business Description
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SLDB has been successfully added to your 